Viridian Therapeutics, Inc.\De (VRDN)Paradigm Biocapital Advisors LP added to its stake +1.71M shares

3.15M

Shares reported · +1.71M vs prior quarter

1.3%

Disclosed portfolio weight

$61.6M

Reported value

Holdings as of

Mar 31, 2026

Filed

May 15, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 5, 2026Company filing · Form 8-K · ResultsReported its results
2. May 6, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)

What came next

1. May 24, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
2. May 27, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
3. Aug 6, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Viridian Therapeutics, Inc.\De

For Viridian Therapeutics, Inc.\De, OQRO holds 4 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VRDN page.

How this filing works

• SEC Form 13F

Other disclosures at Viridian Therapeutics, Inc.\De

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 29, 2026
• SEC Form 13F-HRMay 15, 2026

Everything OQRO holds on this company is on its VRDN page.